(Q37484571)

20 August 2017

1 reference

title

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis (English)

1 reference

20 August 2017

0 references

0 references

Richard A Rudick

1

1 reference

PubMed ID

19446274

20 August 2017

Chris H Polman

series ordinal

2

1 reference

20 August 2017

1 June 2009

1 reference

20 August 2017

1 reference

20 August 2017

8

1 reference

20 August 2017

545-559

1 reference

20 August 2017

6

1 reference

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

20 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Treatment optimization in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Clinical characteristics of responders to interferon therapy for relapsing MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Optimization of treatment with interferon beta in multiple sclerosis. Usefulness of automatic system application criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Defining interferon beta response status in multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

MRI activity and neutralising antibody as predictors of response to interferon treatment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Switching to second-line therapies in interferon-beta-treated relapsing-remitting multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

MRI relapses have significant pathologic and clinical implications in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Baseline MRI predicts future attacks and disability in clinically isolated syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Optimizing the association between disability and biological markers in MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Defining the response to multiple sclerosis treatment: the role of conventional magnetic resonance imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Neutralizing antibodies against interferon β: fluctuation is modest and titre dependent

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Multiplex analysis of expression of three IFNbeta-induced genes in antibody-positive MS patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Potential for interferon beta-induced serum antibodies in multiple sclerosis to inhibit endogenous interferon-regulated chemokine/cytokine responses within the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Multiple sclerosis: relating MxA transcription to anti-interferon-beta-neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Predictive markers for response to interferon therapy in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

A comparative study of the relative bioavailability of different interferon beta preparations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

The clinical impact of interferon beta antibodies in relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Downregulation of VLA-4 on T cells as a marker of long term treatment response to interferon beta-1a in MS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of interferon beta-1b in patients with secondary progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

CD8+ T cell activation correlates with disease activity in clinically isolated syndromes and is regulated by interferon-beta treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Saliva soluble HLA as a potential marker of response to interferon-beta 1a in multiple sclerosis: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Chemokine receptor CCR5 in interferon-treated multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Could cytokines levels or adhesion molecules expression be predictor of IFN-beta treatment response in multiple sclerosis patients?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Transcription-based prediction of response to IFNbeta using supervised computational methods

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Translation towards personalized medicine in Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Switching algorithms: from one immunomodulatory agent to another

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Relapsing-remitting multiple sclerosis: what is the potential for combination therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Combination therapy for the treatment of multiple sclerosis: challenges and opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Combination therapy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

1 reference

7 January 2021

Combination therapy for multiple sclerosis: the treatment strategy of the future?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Statins to treat multiple sclerosis: friend or foe?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970082-1

7 January 2021

10.1016/S1474-4422(09)70082-1

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19446274